TY  - JOUR
AU  - Aguado de la Rosa, Carlos
AU  - Cruz Castellanos, Patricia
AU  - Lázaro-Quintela, Martín
AU  - Dómine, Manuel
AU  - Vázquez Estévez, Sergio
AU  - López-Vivanco, Guillermo
AU  - Fírvida Pérez, José Luis
AU  - Alonso Romero, José Luis
AU  - Ferrera Delgado, Lioba
AU  - García Girón, Carlos
AU  - Diz Taín, Pilar
AU  - Álvarez Álvarez, Rosa
AU  - Mut Sanchís, Pilar
AU  - Fernández Cantón, Inmaculada
AU  - Manrique Abós, Isabel
AU  - Martínez Aguillo, Maite
AU  - Gómez-Aldaraví Gutiérrez, Lorenzo
AU  - Ortega Granados, Ana Laura
AU  - Álvarez Cabellos, Ruth
AU  - García Sebastián, Arancha
AU  - García Sifuentes, Luis Fernando
AU  - Reguart, Noemí
PY  - 2022
DO  - 10.1016/j.lungcan.2022.09.010
UR  - http://hdl.handle.net/10668/22355
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - To determine the incidence of ALK translocations in patients with advanced/metastatic NSCLC in Spain, to describe the clinical characteristics of these patients, and to evaluate the effectiveness and safety of treatment with crizotinib in a real-world...
LA  - en
KW  - ALK-positive non-small cell lung cancer (NSCLC)
KW  - Anaplastic lymphoma kinase
KW  - Crizotinib
KW  - Incidence
KW  - Real-world
KW  - Tyrosine kinase inhibitors
KW  - Humans
KW  - Female
KW  - Male
KW  - Crizotinib
KW  - Retrospective Studies
KW  - Quality of Life
KW  - Anaplastic Lymphoma Kinase
KW  - Prospective Studies
KW  - Spain
KW  - Lung Neoplasms
KW  - Protein Kinase Inhibitors
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Transaminases
TI  - Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
TY  - research article
VL  - 173
ER  -